Imaging-derived Biomarkers Associated with Atrial FIBROsis, Structural Remodeling and the Risk of Cardioembolic Events in Patients with Atrial Fibrillation – the FIBROS Study

Balázs Oltean-Péter 1 , 3 , Szilamér Korodi 1 , 2 , István Benedek Jr 1 , 3 , Erzsébet Lázár 1 , 3 , Johanna Kéri 1 , 3 , Annamária Pakucs 1 , 3 , István Kovács 1 , 2 , Lehel Bordi 1 , 2 , Adriana Mitre 1 , Imre Benedek 1 , 2 , Theodora Benedek 1 , 2 ,  and István Benedek 1 , 3
  • 1 University of Medicine and Pharmacy, , Tîrgu Mureș, Romania
  • 2 Center of Advanced Research in Multimodality Cardiac Imaging, Cardio Med Medical Center, , Tîrgu Mureș, Romania
  • 3 Clinic of Hematology and Bone Marrow Transplantation Unit, , Tîrgu Mureș, Romania


Recent studies demonstrated that despite restoration of the sinus rhythm, patients with a positive history of atrial fibrillation (AF) are still at risk of thromboembolic events. The primary objective of this study is to identify new imaging-derived biomarkers provided by modern imaging technologies, such as cardiac computed tomography angiography, delayed enhancement magnetic resonance imaging, or speckle tracking echocardiography, as well as hematological biomarkers, associated with the risk of intracavitary thrombosis in patients with AF, in order to identify the imaging-derived characteristics associated with an increased risk of cardioembolic events. Imaging data collected will be post-processed using advanced techniques of computational modeling, in order to fully characterize the degree of structural remodeling and the amount of atrial fibrosis. The primary endpoint of the study is represented by the rate of thromboembolic events. The rate of cardiovascular death, the rate of major adverse cardiovascular events, and the rate of AF recurrence will also be determined in relation to the degree of structural remodeling and atrial fibrosis.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.

  • 2. Chamberlain AM, Gersh BJ, Alonso A, et al. Decade-long trends in atrial fibrillation incidence and survival: a community study. Am J Med. 2015;128:260-267.

  • 3. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.

  • 4. Benjamin J. Hirsh, MD, Robert S, et al. Fibrotic Atrial Cardiomyopathy, Atrial Fibrillation, and Thromboembolism. Elsevier. 2015;65:2239-2251.

  • 5. Disertori M, Franzosi MG, Barlera S, et al. Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSIAF trial. BMC Cardiovasc Disord. 2013;13:28.

  • 6. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J. 2015;36:288-296.

  • 7. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120-129.

  • 8. Haemers P, Hamdi H, Guedj K, et al. Atrial fibrillation is associated with the fibrotic remodelling of adipose tissue in the subepicardium of human and sheep atria. Eur Heart J. 2017;38:53-61.

  • 9. Auer J. Fat: an emerging player in the field of atrial fibrillation. Eur Heart J. 2017;38:62-65.

  • 10. Luscher FT. Atrial fibrillation beyond the arrhythmia: hypercoagulability, adipose tissue, and fibrotic remodeling. Eur Heart J. 2017;38:1-3.

  • 11. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335-2345.

  • 12. Tan AY, Zimetbaum P. Atrial fibrillation and atrial fibrosis. J Cardiovasc Pharmacol. 2011;57:625-629.

  • 13. Mikhail S. Dzeshka, Gregory Y.H. Lip, et al. Cardiac Fibrosis in Patients With Atrial Fibrillation. JACC. 2015;66:943-959.

  • 14. Filgueiras-Rama D, Price NF, Martins RP, et al. Long-term frequency gradients during persistent atrial fibrillation in sheep are associated with stable sources in the left atrium. Circ Arrhythm Electrophysiol. 2012;5:1160-1167.

  • 15. Gramley F, Lorenzen J, Jedamzik B, et al. Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol. 2010;19:102-111.

  • 16. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722-731.

  • 17. Daccarett M, Badger TJ, Akoum N, et al. Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol. 2011;57:831-838.

  • 18. Spragg DD, Khurram I, Nazarian S. Role of Magnetic Resonance Imaging of Atrial Fibrosis in Atrial Fibrillation Ablation. Arrhythm Electrophysiol Rev. 2013;2:124-127.

  • 19. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104:2886-2891.

  • 20. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174-180.

  • 21. Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010;31:1730-1736.

  • 22. Jesel L, Arentz T, Herrera-Siklody C, et al. Do atrial differences in endothelial damage, leukocyte and platelet activation, or tissue factor activity contribute to chamber-specific thrombogenic status in patients with atrial fibrillation?. J Cardiovasc Electrophysiol. 2014;25:266-270.

  • 23. Akar JG, Jeske W, Wilber DJ. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol. 2008;51:1790-1793.

  • 24. Pathak RK, Mahajan R, Lau DH, Sanders P. The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol. 2015;31:203-210.

  • 25. Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10:90-100.

  • 26. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722-731.

  • 27. Spronk HM, De Jong AM, Verheule S, et. al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J. 2017;38:38-50.

  • 28. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172-1179.

  • 29. Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol. 2015;65:2239-2251.


Journal + Issues